Pillar 1 - FTO (new thread), page-2955

The FTO opportunity is the CPACS opportunity.

If the likelihood of Bisantrene having an FTO-inhibitor competitor was 10% in the next 4-years, then a CPACS competitor is 0.1%.

A CPACS drug doesn't need to have FTO-inhibition as it's anti-cancer synergy, but Bisantrene does. Pure FTO-inhibition is potentially cardiotoxic in synergy with other drugs. FTO-inhibition as your anti-cancer synergy is good because it plays a central role in almost all cancer types and resistance across a broad spectrum of therapies.

Bisantrene synergising with Doxorubicin to more effectively kill cancer proves FTO as a valid therapy target, and validates all the preclinical studies supporting the combination of FTO-inhibitors with 26 drug classes. Doxorubicin is the most-dosed drug globally, so piggybacking off 10% of it's dosing each year is worth hundreds of millions or even billions in sales. Pharma companies want first-in-class drugs with huge markets and no competition.